Aziz Sancar eliminates tumors in mice

Aziz Sancar’s widely shared mouse-cancer result is real, but it is narrower than viral posts made it sound. The work comes from Sancar’s lab at the University of North Carolina and describes a preclinical glioblastoma study, not a treatment shown to work in people. UNC said on January 2 that combining temozolomide, the standard chemotherapy for glioblastoma, with 5-Ethynyl-2′-deoxyuridine, or EdU, produced “unprecedented survival and cancer remission” in several preclinical models. ### What exactly did Sancar’s team report? UNC said the study tested the drug pair in glioblastoma cell lines and mouse models, as well as patient tumor tissue grown in an organotypic brain-slice platform. The institution said the research was led by Nobel laureate Aziz Sancar and published in the Proceedings of the National Academy of Sciences. (news.unchealthcare.org) The bioRxiv preprint describes the same core finding in more technical terms. It says TMZ plus EdU outperformed either drug alone across three orthotopic glioblastoma xenograft models and in patient-derived tumor tissue, and that the combination “could be effective alongside standard of care TMZ in patients with GBM.” That last point is a research conclusion, not evidence from a human trial. (news.unchealthcare.org) ### What is EdU, and why is it unusual here? EdU is usually known as a laboratory chemical used to label dividing cells, not as an approved cancer medicine. UNC said Sancar’s group had previously shown that EdU could enter the brain, kill cells within glioblastoma tumors, and leave healthy brain tissue unharmed in tumor samples removed from patients. (biorxiv.org) Temozolomide, or TMZ, is the standard chemotherapy used with radiation for glioblastoma, according to UNC. The preprint says the rationale for combining the two is that they engage distinct DNA-repair pathways, which the authors say produced stronger anti-tumor effects than either agent alone in preclinical testing. ### Did the mice really become tumor-free and survive 250-plus days? (news.unchealthcare.org) UNC’s account supports the broad claim that some treated mice had complete remissions with very long survival for this kind of experiment. Secondary reports based on the UNC release said detectable cancer was gone by day 23 in one model and that all mice in that treatment arm survived beyond 250 days; another model reportedly remained tumor-free after 170 days. (news.unchealthcare.org) The more careful way to say it is this: Sancar’s group reported complete tumor clearance in specific preclinical models, under specific dosing conditions, in mice implanted with human glioblastoma cells. That is stronger than a routine early mouse result, but it is still a preclinical result. ### Does this mean there is now a cure for glioblastoma? (tinygems.com) Glioblastoma remains one of the deadliest brain cancers, and UNC said current treatment has changed little in about 20 years. The institution said only about 7% of patients survive more than five years after diagnosis, which is why the result drew attention. No public source I found shows that this EdU-plus-TMZ regimen has entered human clinical trials. (news.unchealthcare.org) The preprint also notes that Sancar and co-authors filed a provisional patent application in October 2025 covering methods of treating central nervous system cancers with EdU and temozolomide. ### What about the other breakthroughs bundled into the viral thread? KAIST researchers did report work on reprogramming colon cancer cells toward a more normal state, but that is a separate line of research from Sancar’s glioblastoma work and comes from a different team and disease area. (news.unchealthcare.org) Mariano Barbacid’s pancreatic-cancer work also circulated widely this year, but EL PAÍS reported in February that public claims around that mouse study created false expectations and that the treatment remained experimental. (biorxiv.org) The paper had described results in mice, while patients and families sought access to something not yet available as a therapy. (pulse.mk.co.kr) ### So what should readers take from the claim that “tumors were eliminated”? The verified version is straightforward. Aziz Sancar’s lab reported a promising preclinical glioblastoma result in mice and tumor models using EdU plus temozolomide, with complete remissions in some models and unusually long survival. The next concrete milestone would be formal follow-on preclinical work and, if regulators and investigators proceed, a first human trial. (english.elpais.com) As of May 22, 2026, the public record I found supports the mouse result but does not support saying the treatment has been proven in patients. (news.unchealthcare.org)